Liver Cirrhosis (Gastrointestinal) - Drugs In Development, 2021

Liver Cirrhosis (Gastrointestinal) - Drugs In Development, 2021

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis (Gastrointestinal) - Drugs In Development, 2021, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape.

Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Liver Cirrhosis (Gastrointestinal) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Liver Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 2, 12, 6, 1, 1, 16 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Liver Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cirrhosis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Liver Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liver Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liver Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cirrhosis (Gastrointestinal)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liver Cirrhosis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liver Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Introduction
Liver Cirrhosis - Overview
Liver Cirrhosis - Therapeutics Development
Liver Cirrhosis - Therapeutics Assessment
Liver Cirrhosis - Companies Involved in Therapeutics Development
Liver Cirrhosis - Drug Profiles
Liver Cirrhosis - Dormant Projects
Liver Cirrhosis - Discontinued Products
Liver Cirrhosis - Product Development Milestones
Appendix

List Of Tables


Number of Products under Development for Liver Cirrhosis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Liver Cirrhosis - Pipeline by Baylx Inc, 2021
Liver Cirrhosis - Pipeline by Bristol-Myers Squibb Co, 2021
Liver Cirrhosis - Pipeline by Candel Therapeutics, 2021
Liver Cirrhosis - Pipeline by CAR-T (Shanghai) Biotechnology Co Ltd, 2021
Liver Cirrhosis - Pipeline by CellionBioMed Inc, 2021
Liver Cirrhosis - Pipeline by China Immunotech Co Ltd, 2021
Liver Cirrhosis - Pipeline by D&D Pharmatech Co Ltd, 2021
Liver Cirrhosis - Pipeline by Elixirgen Therapeutics Inc, 2021
Liver Cirrhosis - Pipeline by Galectin Therapeutics Inc, 2021
Liver Cirrhosis - Pipeline by Galecto Inc, 2021
Liver Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, 2021
Liver Cirrhosis - Dormant Projects, 2021
Liver Cirrhosis - Discontinued Products, 2021

List Of Figures


Number of Products under Development for Liver Cirrhosis, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021

Global Microneedle Drug Delivery Systems Market 2023

DescriptionThe global Microneedle Drug Delivery Systems Market is anticipated to experience significant growth, expanding from USD 2.59 billion in 2022 to USD 3.82 billion by 2029, at a CAGR of

USD 1875 View Report

Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1) - Drugs in Development, 2021

Vascular Endothelial Growth Factor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor or Protein Tyrosine Kinase Receptor flk 1 or VEGFR2 or CD309 or KDR or EC

USD 3500 View Report

Cirrhosis (Gastrointestinal) - Drugs in Development, 2021

Cirrhosis (Gastrointestinal) - Drugs in Development, 2021Cirrhosis (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Cirrhosis pipeline landscape.The report provides comprehensive information on the therapeutics under development

USD 2000 View Report

COVID-19 Outbreak-Global Liver Cirrhosis Therapeutics Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020

The Liver Cirrhosis Therapeutics market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.Under COVID-19 outbreak globally,

USD 3660 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available